MRT5500 mRNA Vaccine Description
Translate Bio has begun to produce multiple mRNA constructs and will use its mRNA platform to discover, design, and manufacture SARS-CoV-2 vaccine candidates.
Using our proprietary mRNA therapeutic platform (MRTTM), we create mRNA that encodes functional proteins. Our mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease, said the company.
Our MRTTM platform has been in development for over ten years, initially at Shire, and then at Translate since 2016. With the scientific founders of the MRTTM platform part of our leadership team, we have built on Shire’s initial pioneering work and investment to advance our goal of bringing our transformative mRNA approach to patients.
Additionally, the MRT platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as oncology and infectious diseases; in the case of the latter, we have a collaboration with Sanofi Pasteur to develop novel mRNA vaccines for all infectious diseases, including SARS-CoV-2, the novel coronavirus responsible for the disease known as COVID-19.
Sanofi will provide deep vaccine expertise and support from its external research networks to advance vaccine candidates for potential further development.
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
MRT5500 mRNA Vaccine Indication
This novel mRNA vaccine candidate will be used to prevent COVID-19 disease caused by the SARS-CoV-2 virus.
MRT5500 mRNA Vaccine News
April 19, 2021 - Study: Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. Finding: MRT5500, elicited potent nAbs as measured in neutralization assays in all three preclinical models and more importantly, protected against SARS-CoV-2-induced weight loss and lung pathology in hamsters. In addition, MRT5500 elicited TH1-biased responses in both mouse and non-human primate (NHP), thus alleviating a hypothetical concern of potential vaccine-associated enhanced respiratory diseases known associated with TH2-biased responses. These data position MRT5500 as a viable vaccine candidate for entering clinical development.
March 12, 2021 - Sanofi Pasteur and Translate Bio announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. The Companies expect interim results from this trial in the third quarter of 2021.
August 6, 2020 - The Company announced continued progress in advancing COVID-19 vaccine candidates supports the goal to initiate first-in-human clinical trial Q4 2020.
July 20, 2020 - Translate Bio announced the closing of a previously announced expansion of the collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for all infectious disease pathogens, following notice of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Sanofi received exclusive worldwide rights for infectious disease mRNA vaccines and will pay for all costs during the collaboration term.
March 27, 2020 - “The Translate Bio and Sanofi Pasteur teams have generated encouraging preclinical data across multiple infectious disease targets as part of our ongoing mRNA vaccine collaboration. This work will serve as a strong foundation as we direct joint research efforts against COVID-19 to help address this public health threat,” said Ronald Renaud, chief executive officer of Translate Bio. “Our collaborative efforts to combat COVID-19 will leverage Translate Bio’s innovative mRNA platform as well as Sanofi’s vaccine expertise and ongoing COVID-19 research with the goal of advancing a novel mRNA vaccine rapidly to the clinic.”